IBL-100

N/A

Report date: 2025/06/11 10:20:06
NME

Base Information

Drug NameIBL-100
Drug Alias NamePim1 inhibitors (Centro Nacional de Investigaciones Oncologicas)pan-PIM kinase inhibitors (Inflection Biosciences)Pim kinase inhibitors (CNIO)ETP-39010IBL-100 +[6] 
ClassificationSmall molecules
Mechanisms of ActionProto-oncogene serine/threonine-protein kinase Pim-1 inhibitorsAnticancer protein kinase inhibitors
TargetsProto-oncogene serine/threonine-protein kinase Pim-1
Therapy Area/IndicationsInflammationAutoimmune DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIrelandSpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCentro Nacional De Investigaciones Oncologicas
China Registration ClassN/A

Develop Information

Active CompaniesCentro Nacional De Investigaciones OncologicasInflection Biosciences Ltd
Inactive CompaniesN/A
Active IndicationsInflammationAutoimmune DiseasesNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A